Xarelto Lawsuit Update: Pretrial Orders for Phila. Mass Tort Group Released
New Pre-Trial Orders for Xarelto Phila Mass Tort Group
New pre-trial orders have been issued for the Philadelphia mass tort group that is consolidating Xarelto internal bleeding lawsuits.
A new pretrial order was issued for the Philadelphia mass tort litigation against the manufacturers of the blood thinner Xarelto. This pretrial order, Case Management Order no.7, was issued on August 21, 2015 and appoints a Discovery Master for the Xarelto Litigation Mass Tort Program. The new Discovery Master is listed as the Honorable Jane Cutler Greenspan. This order is applicable to all cases filed in the mass tort litigation in the Civil Trial Division of the Philadelphia Court of Common Pleas.
The investigation process for evidence before a trial begins is referred to as the discovery process. It is common for complex litigation cases to appoint a discovery master. The discovery master has the power to implement and manage a plan for the discovery process, issue orders to resolve discovery disagreements, submit recommendations to the presiding judge, and in general monitor the discovery process. The role of the discovery master is more of a management role than a judiciary role in the trial process.
The Xarelto Litigation
There are currently 430 cases filed in the Philadelphia mass tort litigation. These cases are able to be consolidated because they all make similar allegations against the same defendants, in these cases the manufacturers of the blood thinner Xarelto, Bayer AG and Janssen Pharmaceuticals. The lawsuits all commonly allege that the blood thinner Xarelto causes severe internal bleeding which can lead to serious injuries and death in patients. They also allege that the manufacturers did not adequately warn patients and doctors about the real risks of the drug and were reckless and negligent by releasing the drug to market without an antidote.
Lawsuits Allege Xarelto is More Dangerous
Xarelto is a part of a new class of blood thinners called Xa inhibitors. Xa inhibitors work differently than other blood thinners on the market because they keep the blood from clotting by blocking the chemical in the blood that is responsible for making it clot, thrombin. By blocking thrombin, Xarelto completely takes away the blood's ability to clot. This is dangerous because the manufacturers of Xarelto did not develop an antidote to counteract the drug's anticoagulant effects, meaning that if a patient experiences an internal bleeding injury while Xarelto is active in their system, there is no way to stop the bleeding. This is a much more dangerous situation than the one that patients taking Warfarin are in. If a patient suffers an internal bleeding injury while taking Warfarin, a doctor can administer vitamin K and the patient's blood will clot again.
"If the manufacturers of Xarelto were aware of the dangers of the drug yet released it to market anyway, they deserve to be brought to justice." Xarelto attorney Marc Goldich said, "Do not hesitate to contact us if you believe that you or a loved one have been harmed by Xarelto."
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.